Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Gapping up/down: SKX +10%, ATVI +10%, MT +4% and NVDA +2% after earnings, MJN +5% after M&A news; YELP -10%, CERN -7%, SGEN -7% and ZAYO -3% after earnings<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>CTRL</strong> +15%, <strong>INFN</strong> +11.7%, <strong>SKX</strong> +10.4%, <strong>HDP</strong> +10.1%, <strong>ATVI</strong> +10.1%, <strong>QUOT</strong> +10.1%, <strong>SWIR</strong> +9.7%, <strong>ASYS</strong> +8.1%, <strong>TRVG</strong> +7.8%, <strong>RPD</strong> +7.5%, <strong>IMMU</strong> +7%</li><li><strong>ATEN</strong> +7%, <strong>ELLI</strong> +5.5%, <strong>CPN</strong> +4.7%, <strong>ICHR</strong> +4.5%, <strong>NE</strong> +4.4%, <strong>COLM</strong> +4.4%, <strong>TLND</strong> +3.9%, <strong>MT</strong> +3.6%, <strong>FLR</strong> +3.3%, <strong>ARCW</strong> +3.2%, <strong>RGC</strong> +3.2%, <strong>INVA</strong> +2.7%</li><li><strong>ESNT</strong> +2.7%, <strong>NVDA</strong> +2.4%, <strong>JCOM</strong> +2%, <strong>LPLA</strong> +1.9%, <strong>VRSN</strong> +1.8%, <strong>CPST</strong> +1.6%, <strong>NWSA</strong> +1.6%, <strong>NR</strong> +1.2%, <strong>EXPE</strong> +0.9%, <strong>AON</strong> +0.7%, <strong>MIME</strong> +0.6%, <strong>NTT</strong> +0.6%</li></ul><p><strong>M&A news</strong>:</p><ul><li><strong>MJN</strong> +5.2% (to be acquired by Reckitt Benckiser (RBGLY) for $90 per share)</li></ul><p><strong>Select metals/mining stocks trading higher</strong>:</p><ul><li><strong>FCX</strong> +4.2%, <strong>VALE</strong> +3.9%, <strong>GFI</strong> +2.4%, <strong>RIO</strong> +1.9%, <strong>HMY</strong> +1.5%</li></ul><p><strong>Select oil/gas related names showing strength</strong>:</p><ul><li><strong>WLL</strong> +2.5%, <strong>PBR</strong> +2.2%, <strong>RIG</strong> +1.9%, <strong>CHK</strong> +1.3%, <strong>HAL</strong> +0.8%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>SHLD</strong> +35.2% (announces 2nd phase of strategic restructuring program, targeting cost reductions of at least $1.0 billion on an annualized basis and enters into amended credit facility, sees upside Q4 sales)</li><li><strong>CBR</strong> +9.4% (Lone Star Value discloses 5.4% active stake, says has engaged, and may continue to engage, in general discussions with the Board and management team, including with respect to the composition of the Board)</li><li><strong>IMMU</strong> +9.1% (enters into exclusive global licensing agreement with Seattle Genetics (SGEN))</li><li><strong>HXL</strong> +3.4% (authorizes $300 million of additional share repurchases)</li><li><strong>AMD</strong> +2.7% (NVDA sympathy)</li><li><strong>AVEO</strong> +1.1% (announces updates for its lead drug candidate, tivozanib; 'Pivotal TIVO-3 Trial Enrollment Proceeding Substantially Ahead of Schedule', not revising anticipated topline data time)</li><li><strong>JBLU</strong> +0.7% (reports January traffic)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>GTE</strong> +5.5% (upgraded to Outperform from Neutral at Credit Suisse)</li><li><strong>QEP</strong> +0.6% (upgraded to Outperform at Wells Fargo)</li><li><strong>BYD</strong> +0.5% (initiated with a Buy at SunTrust)</li></ul><p><strong>Gapping down<br/> In reaction to disappointing earnings/guidance</strong>:</p><ul><li><strong>ONVO</strong> -17.2%, <strong>RSYS</strong> -15.3%, <strong>YELP</strong> -9.7%, <strong>UBNT</strong> -9.6%, <strong>CATM</strong> -7.3%, <strong>CERN</strong> -7%, <strong>MX</strong> -6.6%, <strong>SGEN</strong> -6.5%, <strong>IPAS</strong> -6.3%, <strong>MPWR</strong> -5.6%, <strong>CYBR</strong> -5.4%, <strong>MCFT</strong> -5%</li><li><strong>ZNGA</strong> -4.8%, <strong>ZAYO</strong> -3.2%, <strong>APTI</strong> -3.2%, <strong>SANW</strong> -3.2%, <strong>ALDW</strong> -2.6%, <strong>EGAN</strong> -2.4%, <strong>P</strong> -1.8%, <strong>TBBK</strong> -1.7%, <strong>CARB</strong> -1.4%, <strong>MHK</strong> -1.3%, <strong>AXL</strong> -0.9%, .</li></ul><p><strong>Select financial related names showing weakness</strong>:</p><ul><li><strong>DB</strong> -2.2%, <strong>SAN</strong> -2.2%, <strong>RBS</strong> -2%, <strong>ING</strong> -1.7%, <strong>CS</strong> -1.6%, <strong>LYG</strong> -1.2%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>MJN</strong> 5.2% (to be acquired by Reckitt Benckiser (RBGLY) for $90 per share)</li><li><strong>BSTG</strong> -37.6% (prices public offering with expected total gross proceeds of approx. $8.0 mln at $0.40/share)</li><li><strong>TCON</strong> -17.5% ( reports top-line results from a randomized Phase 2 clinical trial of TRC105 in recurrent glioblastoma (GBM) funded and conducted by the Clinical Therapy Evaluation Program (CTEP) of the National Cancer Institute )</li><li><strong>ICPT</strong> -11.3% (will provide an update on the Phase 3 REGENERATE trial of obeticholic acid in NASH patients with liver fibrosis during a conference call today)</li><li><strong>NDLS</strong> -9% (completes $18.5 mln private placement of Series A Convertible Preferred Stock and warrants to L Catterton, amends credit facility, and preannounces in-line Q4 revs; commences common stock offering; size not disclosed)</li><li><strong>BTX</strong> -8.6% (commences common stock offering)</li><li><strong>CLF</strong> -5.8% (upsizes offering by 5 mln shares and prices 55 mln shares of common stock at $10.75 per share)</li><li><strong>NBIX</strong> -0.8% (Neurocrine Biosci and BIAL enter into an exclusive licensing agreement for the development and commercialization of opicapone in North America)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>TWTR</strong> -1.9% (downgraded to Sell from Neutral at Citigroup)</li><li><strong>TEVA</strong> -1.1% (downgraded to Neutral from Buy at Mizuho)</li><li><strong>GBDC</strong> -0.9% (downgraded to Mkt Perform from Outperform at Raymond James)</li><li><strong>SBUX</strong> -0.6% (downgraded to Hold from Buy at Argus)</li></ul></td> </tr></table>"